the Paperwork Reduction Act of 1995, no persons are required to respond to a c





Approved for use through 10/31/2002, QMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT/OF COMMERCE

REQUEST

FOR

CONTINUED EXAMINATION (RCE) TRANSMITTAL

Address to: Commissioner for Patents **Box RCE** Washington, DC 20231

ollection of information unless it	displays a valid OMB control number.	ë
Application Number	09/576/101	
Filing Date	May 22, 2000	
First Named Inventor	Andreas Suhrbier	
Art Unit	1644	
Examiner Name	P. Huynh	
Attorney Docket Number	FBRC:004USC1	

This is a Request for Continued Examination (RCE) under 37 CFR 1.114 of the above-identified application. Request for Continued Examination (RCE) practice under 37 CFR 1.114 does not apply to any utility or plant application filed prior to June 8, 1995, or to any design application. See Instruction Sheet for RCEs (not to be submitted to the USPTO) on page 2 Submission required under 37 CFR 1.114 RECEIVED a. Previously submitted NOV 2 6 2002 Consider the amendment(s)/reply under 37 CFR 1.116 previously filed on _____ (Any unentered amendment(s) referred to above will be entered). Consider the arguments in the Appeal Brief or Reply Brief previously filed on __TECH_CENTER_1600/2900 Other b. | Enclosed Amendment/Reply Information Disclosure Statement (IDS) Affidavit(s)/Declaration(s) Other Drawings - 29 sheets; Amended Specification; Amended Claims; Pending Claims; & return postcard Miscellaneous Suspension of action on the above-identified application is requested under 37 CFR 1.103(c) for a period of _____ months. (Period of suspension shall not exceed 3 months; Fee under 37 CFR 1.17(i) required.) Fees The RCE fee under 37 CFR 1.17(e) is required by 37 CFR 1.114 when the RCE is filed. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 50-1212/FBRC:004USC1 if check is missing or insufficient. i. RCE fee required under 37 CFR 1.17(e) ii. 11/26/2002 AUDNDAF1 00000165 09575101 Extension of time fee (37 CFR 1.136 and 1.17) Other iii. 740.00 OP 01 FC:1801 b. Check in the amount of \$ 1,660.00 enclosed c. Payment by credit card (Form PTO-2038 enclosed) WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED Name (Print /Type) Thomas M. Boyce Registration No. (Attorney/Agent) 43,508 Michael R. Krawzsenck Signature Date November 21, 2002 CERTIFICATE OF MAILING OR TRANSMISSION I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as frst class mail in an envelope addressed to: Commissioner For Patents, Box RCE, Washington, DC 20231, or facsimile transmitted to the U.S. Patent and Trademark Office on the date shown below. Michael R. Krawzsenek Name (Print/Type) Signature Date November 21, 2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND Fees and Completed Forms to the following address: Assistant Commissioner for Patents, Box RCE, Washington, DC 20231.



RECEIVED

NOV 2 6 2002

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ANDREAS SUHRBIER, SCOTT ANTHONY THOMSON, RAJIV KHANNA SCOTT RENTON BURROWS, BARBARA ELIZABETH HOWIESON COUPAR, DENIS JAMES MOSS

Serial No.: 09/576,101

Filed: May 22, 2000

For: POLYEPITOPE VACCINES

Group Art Unit:

1644

Examiner:

P. Huynh

Atty. Dkt. No.: FBRC:004USC1/TMB

CERTIFICATE OF MAILING 37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below:

November 21, 2002

Date

Michael R. Krawzsenek

SUBMISSION PURSUANT TO 37 C.F.R. § 1.114(A)

Commissioner for Patents Washington, D.C. 20231

Commissioner:

This paper is submitted pursuant to 37 C.F.R. § 1.114(a) and in response to the Office Action ("the Action") dated May 21, 2002, for which the three-month date for response was August 21, 2002. A Request for Continued Examination (RCE) along with the appropriate filling fee is concurrently filed herewith.

11/26/2002 AUONDAF1 00000165 09576101

02 FC:1253

920.00 OP

Also, a petition for a three month extension of time to respond is included herewith along with the required fee. This extension will bring the due date to November 21, 2002, which is within the six-month statutory period. Should such request or the appropriate fees be deficient or absent, consider this paragraph such a request and authorization to withdraw the appropriate fees under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/FBRC:004USC1/TMB.

Reconsideration of the application is respectfully requested.

I. PETITION FOR EXTENSION OF TIME

Pursuant to 37 C.F.R. § 1.136(a), Applicants' petition for an extension of time of three months, to and including November 21, 2002, in which to respond to the Office Action dated May 21, 2002. Pursuant to 37 C.F.R. § 1.17, a check in the amount of \$1,660.00 is enclosed, which is the process fee for a three-month extension of time and the filing fee for the Request for Continued Examination. If the check is inadvertently omitted, or should any additional fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, or should an overpayment be included herein, the Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski Deposit Account No. 50-1212/FBRC:004USC1/TMB.

Reconsideration of the application is respectfully requested.

II. AMENDMENT

Please make the following amendments:

In the Specification:

On page 19, please replace paragraph 73 with the substitute paragraph provided below.

--73. To test this possibility mice (Balb/c) were infected with 10⁴ pfu of Murine cytomegalovirus (MCMV) (K181 strain - Scalzo *et al.* 1995) and left for 5 weeks at which point

2

25233446.1